Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01109992 · ClinicalTrials.gov registry record · Phase 4

Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET

A Phase 4 study, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 4
Development phase
43
Enrollment target

NCT01109992: Completed Phase 4 study, sponsored by Brigham and Women's Hospital.

NCT01109992 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01109992, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 4
Development phase
43 participants
Enrollment target

Study Summary

This is a single-center study of subjects undergoing clinically indicated heart scans for evaluation of known or suspected heart disease. We will also include 10 healthy subjects without known heart disease. We would like to study stress testing of the heart using exercise and a medication called regadenoson. Imaging of the heart will be performed.

Primary Outcome

1. Count of subjects with ischemic ECG changes is reported 2. Count of subjects with systolic blood pressure decrease \> 20 mm Hg is reported 3. Count of subjects with abnormal serum troponin T levels is reported 4. Radiation dose to the staff will be measured using personal dosimeters after the Lexiscan as well as the Lexercise PET study.

Interventions

  • DRUG Exercise plus Regadenoson (Lexercise)
  • DRUG Regadenoson (Lexiscan)

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2011-02
Est. Completion 2017-06-06
Phase Phase 4
Brigham and Women's Hospital

937 total trials

What the finished NCT01109992 record still lists

NCT01109992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 2 interventions - of which Exercise plus Regadenoson (Lexercise) is the first listed.

NCT01109992 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01109992 about?

NCT01109992 is a clinical study titled "Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET". This is a single-center study of subjects undergoing clinically indicated heart scans for evaluation of known or suspected heart disease. We will also include 10 healthy subjects without known heart disease. We would like to study stress testing of the heart using exercise and a medication called re...

What is the current status of trial NCT01109992?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2011-02. Estimated completion is 2017-06-06.

What interventions are being tested in trial NCT01109992?

The interventions under investigation include: Exercise plus Regadenoson (Lexercise) (DRUG), Regadenoson (Lexiscan) (DRUG).

Who is sponsoring clinical trial NCT01109992?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01109992's enrollment target sits among peer trials

43 1371st of 2000 higher than 621 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01109992, the US trial registry maintained by the National Library of Medicine. NCT01109992 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.